Rethinking antivirulence therapies against Pseudomonas aeruginosa: translational challenges and future directions through a state-control framework

With the emergence of post-antibiotic era, antivirulence therapy against Pseudomonas aeruginosa was conceived as a rational escape from the global antimicrobial resistance crisis. Built on the foundation of virulence attenuation/disarmament rather than pathogen elimination, antivirulence therapy has not achieved any tangible clinical translation. This misfortune shows a reproducible pattern rooted in a series of compounding conceptual limitations. This perspective argues that the translational challenges of antivirulence strategies reflect not pharmacological inadequacy, but a fundamental misalignment between therapeutic design and infection biology. We dissect four structurally-interconnected explanations driving this impasse. First, antivirulence agents have been evaluated using defined endpoints that are engineered for bactericidal drugs, rendering precision disarmament strategies invisible by design. Second, P. aeruginosa itself outsmarts and resists single-node perturbations of virulence pathways not through conventional resistance mechanisms but by deploying intricately connected networks that rewire bacterial virulence in response to therapeutic pressure. Thirdly, the aspiration for broad-spectrum antivirulence therapy negates that pseudomonal virulence is neither fixed nor universal, but a shifting, niche-sculpted, and strain-variable phenomenon that defies a universal target. Finally, antivirulence therapies rely heavily on host immunity-mediated bacterial clearance, which is grossly eroded/compromised in patients infected with P. aeruginosa . We argue that clinical translation of antivirulence therapy requires abandoning the reductionist, target-centric paradigm and adopting a state-control framework that treats pseudomonal infections as dynamic, multifactorial, and coupled host-pathogen interactions. This strategic shift, from targeting molecules to redirecting biological trajectories, can potentially reposition antivirulence agents as precision tools for destabilising pathological states and combating P. aeruginosa infections.